NCT06862089 A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
| NCT ID | NCT06862089 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fu Xing Hospital, Capital Medical University |
| Condition | Retained Products of Conception |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2024-10-23 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV). The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.
Eligibility Criteria
Inclusion Criteria: * Recent history of miscarriage or delivery (within the past 8 weeks) * Strong willingness to undergo conservative management * Hemodynamically stable * Signed informed consent form Exclusion Criteria: * Heavy vaginal bleeding (requiring immediate surgical intervention) * Active pelvic or systemic infection (e.g., fever \>38°C, elevated CRP/WBC) * Severe dysfunction of vital organs (heart, liver, or kidney) * Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance) * Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels) * Placenta accreta spectrum disorders diagnosed during current pregnancy * History of uterine artery embolization
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06862089 clinical trial?
This trial is open to female participants only, studying Retained Products of Conception. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06862089 currently recruiting?
Yes, NCT06862089 is actively recruiting participants. Contact the research team at blueberry0801@foxmail.com for enrollment information.
Where is the NCT06862089 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06862089 clinical trial?
NCT06862089 is sponsored by Fu Xing Hospital, Capital Medical University. The trial plans to enroll 120 participants.